Scots say yes to cancer drugs after patients have their say
This article was originally published in Scrip
Executive Summary
Using a new process that involves greater patient input, Scotland's health technology appraisal body, the Scottish Medicines Consortium, has okayed for use on the local NHS three anticancers that England has so far largely rejected for use on its NHS. Ariad's Iclusig (ponatinib), Boehringer Ingelheim's Vargatef (nintedanib) and Bayer's Stivarga (regorafenib) have all been given the green light in Scotland.